person

Leslie L Citrome, MD, MPH

Leslie CitromeLeslie Citrome, MD

ORCID 0000-0002-6098-9266

as of 2026-07-01

Monitor this Ask about this

at a glance

Roles: Principal Investigator, Author

KOL signal score 32

15 publications · 4 high-value

Cross-drug reach: 4 competitor drugs

Synthesized from structured facts only — each point cited above.

Profile

Affiliation

Nathan S Kline Institute for Psychiatric Research and New York University School of Medicine

Roles

Principal Investigator, Author

KOL signal

Publications

15 (4 high-value)

Trial investigator

yes

Publishes on

4 drugs

Brexpiprazole (Rexulti)Cariprazine (Vraylar)Xanomeline-trospium (Cobenfy)Lumateperone (Caplyta)

Trials led

Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility

NCT00308360Phase 4Completed

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

NCT00297947Phase 2, Phase 3Completed

Publications & congress

Aripiprazole Once-Monthly for Patients Diagnosed With Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.

The Journal of clinical psychiatry · 2026 · high-value

Xanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes.

Pharmacopsychiatry · 2025 · high-value

Effects of cariprazine on reducing symptoms of irritability, hostility, and agitation in patients with manic or mixed episodes of bipolar I disorder.

Journal of affective disorders · 2024 · high-value

Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.

The Journal of clinical psychiatry · 2023 · high-value

Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis.

Advances in therapy · 2026

Understanding the Tolerability Profile of Xanomeline-Trospium Combination for the Treatment of Schizophrenia.

The Journal of clinical psychiatry · 2025

Preclinical Evidence for the Use of Brexpiprazole + Antidepressant Treatment for Major Depressive Disorder and Post-Traumatic Stress Disorder: A Systematic Review.

Neuropsychiatric disease and treatment · 2025

Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment.

Neuropsychiatric disease and treatment · 2025

What's in a name? What shall we call xanomeline-trospium combination?

Expert opinion on drug safety · 2025

Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.

Neuropsychiatric disease and treatment · 2025

Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.

Schizophrenia (Heidelberg, Germany) · 2025

Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.

Schizophrenia (Heidelberg, Germany) · 2024

Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?

CNS spectrums · 2016